Related Experiment Video
Updated: Jun 20, 2025
A 3D Organotypic Melanoma Spheroid Skin Model
Published on: May 18, 2018
Advancing immunotherapy for melanoma: the critical role of single-cell analysis in identifying predictive biomarkers
Ru He1, Jiaan Lu1, Jianglong Feng2
1Clinical Medical College, Southwest Medical University, Luzhou, China.
Abstract:
Melanoma, a malignant skin cancer arising from melanocytes, exhibits rapid metastasis and a high mortality rate, especially in advanced stages. Current treatment modalities, including surgery, radiation, and immunotherapy, offer limited success, with immunotherapy using immune checkpoint inhibitors (ICIs) being the most promising. However, the high mortality rate underscores the urgent need for robust, non-invasive biomarkers to predict patient response to adjuvant therapies. The immune microenvironment of melanoma comprises various immune cells, which influence tumor growth and immune response. Melanoma cells employ multiple mechanisms for immune escape, including defects in immune recognition and epithelial-mesenchymal transition (EMT), which collectively impact treatment efficacy. Single-cell analysis technologies, such as single-cell RNA sequencing (scRNA-seq), have revolutionized the understanding of tumor heterogeneity and immune microenvironment dynamics. These technologies facilitate the identification of rare cell populations, co-expression patterns, and regulatory networks, offering deep insights into tumor progression, immune response, and therapy resistance. In the realm of biomarker discovery for melanoma, single-cell analysis has demonstrated significant potential. It aids in uncovering cellular composition, gene profiles, and novel markers, thus advancing diagnosis, treatment, and prognosis. Additionally, tumor-associated antibodies and specific genetic and cellular markers identified through single-cell analysis hold promise as predictive biomarkers. Despite these advancements, challenges such as RNA-protein expression discrepancies and tumor heterogeneity persist, necessitating further research. Nonetheless, single-cell analysis remains a powerful tool in elucidating the mechanisms underlying therapy response and resistance, ultimately contributing to the development of personalized melanoma therapies and improved patient outcomes.
Insights
Single-cell analysis reveals key biomarkers for predicting melanoma treatment response. This technology enhances understanding of the tumor microenvironment, aiding in the development of personalized therapies for melanoma patients.
Area of Science:
- Oncology and Immunology
- Genomics and Bioinformatics
Background:
- Melanoma, a deadly skin cancer, has high mortality rates, especially in advanced stages, necessitating improved treatment strategies.
- Current melanoma treatments, including immune checkpoint inhibitors (ICIs), show limited success, highlighting the need for predictive biomarkers.
- Understanding the melanoma immune microenvironment and cellular mechanisms of immune escape is crucial for therapeutic advancements.
Purpose of the Study:
- To explore the potential of single-cell analysis in identifying robust, non-invasive biomarkers for predicting patient response to melanoma therapies.
- To investigate how single-cell technologies can elucidate tumor heterogeneity and immune microenvironment dynamics in melanoma.
- To advance the diagnosis, treatment, and prognosis of melanoma through novel biomarker discovery.
Main Methods:
- Application of single-cell analysis technologies, including single-cell RNA sequencing (scRNA-seq).
- Identification of rare cell populations, gene expression patterns, and regulatory networks within the melanoma tumor microenvironment.
- Analysis of tumor-associated antibodies and genetic/cellular markers for predictive biomarker potential.
Main Results:
- Single-cell analysis provides deep insights into melanoma progression, immune response, and therapy resistance mechanisms.
- This approach facilitates the discovery of novel cellular and molecular markers with potential as predictive biomarkers for melanoma.
- Tumor-associated antibodies and specific genetic/cellular markers identified show promise for predicting treatment outcomes.
Conclusions:
- Single-cell analysis is a powerful tool for understanding melanoma complexity and developing personalized treatment strategies.
- Despite challenges like RNA-protein discrepancies and tumor heterogeneity, single-cell analysis significantly contributes to identifying predictive biomarkers.
- This technology holds promise for improving patient outcomes in melanoma by enabling more effective, tailored therapies.
